Skip to search formSkip to main contentSkip to account menu

GART protein, human

Known as: EC 6.3.3.1, Phosphoribosylglycinamide Synthetase, Phosphoribosylamine--Glycine Ligase 
Trifunctional purine biosynthetic protein adenosine-3 (1010 aa, ~108 kDa) is encoded by the human GART gene. This protein is involved in the de novo… 
National Institutes of Health

Related topics

Related topics

10 relations
AnabolismCytoplasmic matrixEnzyme GeneGART gene

Broader (3)

Carbon-Nitrogen LigasesPhosphoribosylformylglycinamidine cyclo-ligasePhosphoribosylglycinamide formyltransferase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Charcot-Marie-Tooth–Linked Mutant GARS Is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels
Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the… 
Review
2010
Review
2010
AN EMPIRICAL SYNTHETIC PATTERN STUDY OF GARS (LEPISOSTEIFORMES) AND CLOSELY RELATED SPECIES, BASED MOSTLY ON SKELETAL ANATOMY. THE RESURRECTION OF HOLOSTEI
The comparative osteology, phylogenetic relationships, and historical biogeography of all known fossil and living gars… 
Highly Cited
2007
Highly Cited
2007
Charcot–Marie–Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect
Charcot–Marie–Tooth (CMT) diseases are the most common heritable peripheral neuropathy. At least 10 different mutant alleles of… 
Highly Cited
2006
Highly Cited
2006
Functional Analyses of Glycyl-tRNA Synthetase Mutations Suggest a Key Role for tRNA-Charging Enzymes in Peripheral Axons
Charcot–Marie–Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies… 
Review
2003
Review
2003
Novel antifolate drugs
Antimetabolites are active chemotherapeutic agents for many solid tumor and hematologic malignancies. Folate antagonists, purine… 
Highly Cited
2003
Highly Cited
2003
Loss of folylpoly‐γ‐glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation‐dependent novel antifolates in multiple human leukemia sublines
We have studied the molecular basis of drug resistance in human CCRF‐CEM leukemia cells exposed to high dose intermittent pulses… 
Review
2001
Review
2001
Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness
Treatment with combinations of antiretroviral drugs that target HIV-1 protease and reverse transcriptase enzymes is effective in… 
Review
2001
Review
2001
Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
Pemetrexed disodium (ALIMTA), "pemetrexed") is a novel, multi-targeted antifolate that has demonstrated promising clinical… 
Highly Cited
1999
Highly Cited
1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
Purpose: To determine toxicities, maximally tolerated dose (MTD), pharmacokinetic profile, and potential antitumor activity of… 
Review
1998
Review
1998
New antimetabolites in cancer chemotherapy and their clinical impact.
It is almost 50 years since antimetabolites were first found to have clinical antitumour activity, with Farber's discovery that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)